Cinoxacin [1-ethyl-1,4-dihydro-4-oxo-(1,3)-dioxolo-(4,5g)-cinnoline-3-carboxylic acid] is a synthetic antibacterial agent chemically related to, and with in vitro antibacterial activity similar to, nalidixic acid and oxolinic acid (4, 5, 7, 8) . Several studies have confirmed the efficacy of cinoxacin in the treatment of urinary tract infections caused by susceptible microorganisms (1, 6, 9, 10, 12) . The pharmacology of cinoxacin has been thoroughly studied in human volunteers and in patients with normal renal function (2, 3; P. 0. Madsen and T. B. Kjaer, Proceedings of the 9th International Congress of Chemotherapy, abstr. no. M-666, 1975 ). In patients with impaired renal function it has been shown, after administration of a single dose of 500 mg of cinoxacin, that the elimination half-life of the drug is dependent upon renal function, yet adequate urinary concentrations can be achieved in severe renal impairment (J. J. Szwed, D. E. Brannon, R. S. Sloan, and F. C. Luft, Proceedings of the 10th International Congress of Chemotherapy, abstr. no. 7, 1978) . The purpose of the present study was to investigate the pharmacokinetics of cinoxacin after administration of repeated dosages for 7 Table 1 . Patients were separated into four groups according to creatinine clearance: group 1, >80 ml/ min; group 2, 50 to 79 ml/min; group 3, 30 to 49 ml/ min; and group 4, <30 ml/min. The numbers of patients in the groups were six, seven, four, and five, respectively. Almost all patients suffered from lower urinary tract obstructions due to urethral stricture, carcinoma, or hypertrophy of the prostate or bladder tumor. Some patients had indwelling bladder catheters. All patients had symptoms of urinary tract infections, but not all had positive pretreatment urine cultures (defined as >105 colonies per ml). All patients received an oral dose of cinoxacin (500 mg) every 12 h (9 a.m. and 9 p.m.) for 7 days. The morning dose was administered 1 to 2 h after breakfast. Serum samples were obtained 1, 2, 4, 6, and 12 h after the drug administration on day 1, day 4 or 5, and day 7. Except for day 1, a. serum sample was also taken just before administration of the morning dose. Urine was collected on the same days at 3, 6 , and 12 h after drug administration. To evaluate the safety of the drug, the following laboratory tests were performed before and at the end of the treatment: serum creatinine, blood urea nitrogen, creatinine clearance, total bilirubin, serum glutamic-oxaloacetic transaminase, and alkaline phosphatase, as well as leukocyte count, hemoglobin, and hematocrit.
Assay. Cinoxacin concentrations in serum and urine were determined by a fluorometric method (2 16, 1979 both with Yate's correction for small numbers. P values < 0.05 were considered significant.
RESULTS
The treatment was well tolerated by all patients, and no allergic reactions occurred. Treatment was discontinued in one patient due to nausea and vomiting. However, this condition had appeared before the treatment started. Serum levels of cinoxacin are listed in Table 2 and summarized graphically in Fig. 1 . There was slight accumulation of the drug after repeated doses in groups 2, 3, and 4. However, no significant increases in trough serum concentrations were observed in any of the groups. Elimination half-lives ( t1/2 ), time (tmax) values for the peak serum concentrations (Cmax) after morning dosage, absorption half-lives (t/21,), and calculated accumulation ratios (Re) are listed in Table 3 .
Both tmax and C.. varied somewhat within and among the four groups. Comparing day 1 versus day 7, the values of Cmax, tmax, and t1/2# revealed no significant trends except for a borderline significant difference for Cm,,x values in group 3 (P = 0.05). The calculated values of Rc were very similar to observed accumulation ratios in all groups. Serum concentrations were only slightly greater than the minimal inhibitory concentration for susceptible enterobacteriaceae. In Fig. 2 , the elimination rate constants (kei) for all 22 patients are plotted as a function of endogenous creatinine clearance, and Fig. 3 shows t1I/2f values as a function of serum creatinine. The correlation coefficients, r = +0.835 and r = +0.850, respectively, were highly significant (P < 0.001).
The normalized AUC for each patient is shown as a function of creatinine clearance in Fig. 4 , demonstrating no correlation (r = -0.0096). This indicates that the fraction of active drug absorbed, i.e., the bioavailability, is independent of renal function.
Urinary concentrations and excretion data are summarized in Table 4 . Urine concentrations of cinoxacin in all groups far exceed minimal inhibitory concentrations for susceptible organisms commonly found in urinary tract infections (4, 5, 7, 8, 12) . Twelve-hour urinary recovery on day 1 ranged from 21 to 65% of the administered dose, with the lowest recovery in group 4. The 12-h urinary excretion of cinoxacin correlated significantly with creatinine clearance on day 1 (P < 0.001) but not on days 4, 5, or 7. There was no significant difference in the values of hemoglobin, hematocrit, serum glutamicoxaloacetic transaminase, alkaline phosphatase, leukocyte count, serum creatinine, blood urea nitrogen, creatinine clearance, and total bilirubin at the beginning and end of treatment in any group, except for a significant decrease in serum DISCUSSION This study confirms that cinoxacin is rapidly absorbed from the gastrointestinal tract. Peak cinoxacin levels in serum occurred 2 to 4 h after oral administration. Other studies report peak cinoxacin concentrations within 2 h after drug administration (2, 3). The slightly later peak times in the present study may be due to the older age group involved and also to delayed absorption related to food intake shortly before drug administration in some patients (2) . The absorption half-lives were also somewhat longer in patients with moderate to severe renal impairment (groups 3 and 4), who were often bedridden and in generally poor physical condition. The peak serum concentrations of cinoxacin exceeded the minimal inhibitory concentration for only the most susceptible strains of enterobacteriaceae common in urinary tract infections, whereas the urine concentrations in all groups far exceeded these values. Serum and urine concentrations in this study are generally y-2a46-.M4x comparable to concentrations after corresponding dosages in patients with normal renal function (2, 3, 9; Madsen and Kjaer, Proceedings of the 9th ICC, abstr. no. M-666, 1975 (2) . A minor proportion of the drug is excreted via extrarenal routes. The urinary recovery data reported here are consistent with these findings.
No adverse effects were found in this study after treatment with cinoxacin for 7 days, and the drug appears to be well tolerated, even in patients with markedly impaired renal function. As is the case for nalidixic acid, and depending upon inoculum size and concentration of the drug, cinoxacin treatment may result in selection of resistant microorganisms both in vitro and in vivo (6, 7) . High urine concentrations of these drugs are therefore important for the treatment of urinary tract infections (11) . High concentrations are readily achieved by a cinoxacin dosage of 500 mg every 12 h, a regimen that was well tolerated by uremic individuals in our study. However, since the kidney represents the primary route for excretion of cinoxacin and its metabolites, further studies should be conducted to substantiate cinoxacin safety in uremic patients and to provide guidance for reduced dosage schedules in patients with marked renal failure. 
